ProShare Advisors LLC Acquires 26,018 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ProShare Advisors LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 21.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 146,135 shares of the biopharmaceutical company's stock after purchasing an additional 26,018 shares during the period. ProShare Advisors LLC owned approximately 0.13% of Regeneron Pharmaceuticals worth $104,096,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. Crowley Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at about $36,000. Finally, Private Wealth Management Group LLC boosted its stake in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 39 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating for the company in a report on Wednesday, April 30th. Bank of America cut their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price on the stock. BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th. Finally, Guggenheim cut their price objective on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Trading Up 3.2%

NASDAQ REGN traded up $19.13 during mid-day trading on Tuesday, reaching $614.79. 1,101,817 shares of the stock were exchanged, compared to its average volume of 790,688. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market cap of $66.38 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.34 and a beta of 0.43. The stock has a 50 day simple moving average of $598.10 and a 200-day simple moving average of $680.17. Regeneron Pharmaceuticals, Inc. has a one year low of $520.50 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the prior year, the firm earned $9.55 earnings per share. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.57%. The ex-dividend date of this dividend is Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.